A single course of tandem therapy with low-activity 225Ac-PSMA-617 and full-activity 177Lu-PSMA-617 has enhanced response to PSMA-RLT and minimized xerostomia severity in men with late-stage/end-stage mCRPC [173,194]. The gene discussed is FOLH1; the disease is xerostomia.